Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.

Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5023-30. doi: 10.1128/AAC.00057-12. Epub 2012 Jul 16.


In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.

Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ.

Antimicrob Agents Chemother. 2012 Mar;56(3):1613-5. doi: 10.1128/AAC.05655-11. Epub 2011 Dec 19.


In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.

Kumar M, Mathur T, Barman TK, Ramkumar G, Bhati A, Shukla G, Kalia V, Pandya M, Raj VS, Upadhyay DJ, Vaishnavi C, Chakrabarti A, Das B, Bhatnagar PK.

Antimicrob Agents Chemother. 2012 Nov;56(11):5986-9. doi: 10.1128/AAC.00015-12. Epub 2012 Aug 6.


Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.

Alam MZ, Wu X, Mascio C, Chesnel L, Hurdle JG.

Antimicrob Agents Chemother. 2015 Sep;59(9):5165-70. doi: 10.1128/AAC.01087-15. Epub 2015 Jun 8.


Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.

Mascio CT, Chesnel L, Thorne G, Silverman JA.

Antimicrob Agents Chemother. 2014 Jul;58(7):3976-82. doi: 10.1128/AAC.00124-14. Epub 2014 May 5.


Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Anton PM, O'Brien M, Kokkotou E, Eisenstein B, Michaelis A, Rothstein D, Paraschos S, Kelly CP, Pothoulakis C.

Antimicrob Agents Chemother. 2004 Oct;48(10):3975-9.


In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W.

Antimicrob Agents Chemother. 2014;58(2):892-900. doi: 10.1128/AAC.01830-13. Epub 2013 Nov 25.


Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.

Snydman DR, Jacobus NV, McDermott LA.

Antimicrob Agents Chemother. 2012 Jun;56(6):3448-52. doi: 10.1128/AAC.06257-11. Epub 2012 Mar 5.


Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.

Yin N, Li J, He Y, Herradura P, Pearson A, Mesleh MF, Mascio CT, Howland K, Steenbergen J, Thorne GM, Citron D, Van Praagh AD, Mortin LI, Keith D, Silverman J, Metcalf C.

J Med Chem. 2015 Jun 25;58(12):5137-42. doi: 10.1021/acs.jmedchem.5b00366. Epub 2015 Jun 3.


Efficacy of LFF571 in a hamster model of Clostridium difficile infection.

Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D.

Antimicrob Agents Chemother. 2012 Aug;56(8):4459-62. doi: 10.1128/AAC.06355-11. Epub 2012 May 29.


Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile.

Citron DM, Goldstein EJ.

Diagn Microbiol Infect Dis. 2011 Aug;70(4):554-6. doi: 10.1016/j.diagmicrobio.2011.04.012.


Effects of surotomycin on Clostridium difficile viability and toxin production in vitro.

Bouillaut L, McBride S, Sorg JA, Schmidt DJ, Suarez JM, Tzipori S, Mascio C, Chesnel L, Sonenshein AL.

Antimicrob Agents Chemother. 2015 Jul;59(7):4199-205. doi: 10.1128/AAC.00275-15. Epub 2015 May 4.


In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NC, Fernandes PB, Clement JJ.

Antimicrob Agents Chemother. 1991 Jun;35(6):1108-11.


Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.

Adams HM, Li X, Mascio C, Chesnel L, Palmer KL.

Antimicrob Agents Chemother. 2015 Jul;59(7):4139-47. doi: 10.1128/AAC.00526-15. Epub 2015 May 4.


Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, Rees R, Taylor B, Wood E, Malakun R.

Cochrane Database Syst Rev. 2011 Sep 7;(9):CD004610. doi: 10.1002/14651858.CD004610.pub4. Review.


Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.

Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone KC, Young CL, Critchley IA, Janjic N.

J Antimicrob Chemother. 2009 May;63(5):964-71. doi: 10.1093/jac/dkp042. Epub 2009 Feb 26.


Discovery and development of surotomycin for the treatment of Clostridium difficile.

Knight-Connoni V, Mascio C, Chesnel L, Silverman J.

J Ind Microbiol Biotechnol. 2016 Mar;43(2-3):195-204. doi: 10.1007/s10295-015-1714-6. Epub 2015 Dec 15. Review.


Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004610. Review. Update in: Cochrane Database Syst Rev. 2007;(3):CD004610.


Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Nelson R.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004610. Review. Update in: Cochrane Database Syst Rev. 2011;(9):CD004610.


In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

McVay CS, Rolfe RD.

Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8.

Items per page

Supplemental Content

Write to the Help Desk